Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: Analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36)

Journal of the American College of Cardiology

Volumn 63, Issue 16, 2014, Pages 1644-1653

  O'Malley, Ryan G ^a   Bonaca, Marc P ^a   Scirica, Benjamin M ^a   Murphy, Sabina A ^a   Jarolim, Petr ^a   Sabatine, Marc S ^a   Braunwald, Eugene ^a   Morrow, David A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute coronary syndromes(s); cardiac biomarkers; ischemic heart disease; risk prediction

Indexed keywords

ACUTE CORONARY SYNDROMES(S); CARDIAC BIOMARKERS; ISCHEMIC HEART DISEASE; RISK PREDICTION;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; MALE; PIPERAZINES; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK FACTORS; SODIUM CHANNEL BLOCKERS; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 84898962162     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.12.034     Document Type: Article

References (33)

1. D.A. Morrow, C.P. Cannon, and R.L. Jesse et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes Circulation 115 2007 e356 e375
2. D.A. Morrow, and J.A. de Lemos Benchmarks for the assessment of novel cardiovascular biomarkers Circulation 115 2007 949 952
3. D.A. Morrow, B.M. Scirica, and M.S. Sabatine et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial J Am Coll Cardiol 55 2010 1189 1196
4. A.A. Voors, S. von Haehling, and S.D. Anker et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study Eur Heart J 30 2009 1187 1194
5. A. Gegenhuber, J. Struck, and B. Dieplinger et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure J Card Fail 13 2007 42 49
6. A. Maisel, C. Mueller, and R. Nowak et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial J Am Coll Cardiol 55 2010 2062 2076
7. S.Q. Khan, O.S. Dhillon, and R.J. O'Brien et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study Circulation 115 2007 2103 2110
8. N.G. Morgenthaler Copeptin: a biomarker of cardiovascular and renal function Cong Heart Fail 16 2010 S37 S44
9. D.G. Parkes, and C.N. May Direct cardiac and vascular actions of adrenomedullin in conscious sheep Br J Pharmacol 120 1997 1179 1185
10. S.Q. Khan, R.J. O'Brien, and J. Struck et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study J Am Coll Cardiol 49 2007 1525 1532
11. M.S. Sabatine, D.A. Morrow, and J.A. de Lemos et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease Circulation 125 2011 233 240
12. S.Q. Khan, O. Dhillon, and D. Kelly et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study J Am Coll Cardiol 51 2008 1857 1864
13. D.A. Morrow, B.M. Scirica, and E. Karwatowska-Prokopczuk et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
14. N.G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
15. N.G. Morgenthaler, J. Struck, B. Thomas, and A. Bergmann Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma Clin Chem 50 2004 234 236
16. N.G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay Clin Chem 51 2005 1823 1829
17. B. Dieplinger, J.L. Januzzi, and M. Steinmair et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay Clin Chim Acta 409 2009 33 40
18. M.P. Bonaca, B.M. Scirica, and M.S. Sabatine et al. Prospective evaluation of pregnancy-associated plasma protein-A and outcomes in patients with acute coronary syndromes J Am Coll Cardiol 60 2012 332 338
19. B.M. Scirica, M.S. Sabatine, and P. Jarolim et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial Eur Heart J 32 2011 697 705
20. D.A. Morrow, B.M. Scirica, and E. Karwatowska-Prokopczuk et al. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial Am Heart J 151 2006 1186.e1 1186.e9
21. E.M. Antman, M. Cohen, and P.J. Bernink et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making JAMA 284 2000 835 842
22. M.J. Pencina, R.B. D'Agostino, R.B. D'Agostino, and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2008 157 172
23. N.R. Cook, and P.M. Ridker Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures Ann Intern Med 150 2009 795 802
24. T. Omland, A. Aakvaag, and V. Bonarjee et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide Circulation 93 1996 1963 1969
25. S.K. James, B. Lindahl, and A. Siegbahn et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy Circulation 108 2003 275 281
26. T. Jernberg, B. Lindahl, and A. Siegbahn et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease J Am Coll Cardiol 42 2003 1909 1916
27. A.M. Richards, R. Doughty, and M.G. Nicholls et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group J Am Coll Cardiol 37 2001 1781 1787
28. M. Shimpo, D.A. Morrow, and E.O. Weinberg et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction Circulation 109 2004 2186 2190
29. S. Baldus, C. Heeschen, and T. Meinertz et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes Circulation 108 2003 1440 1445
30. C. Heeschen, S. Dimmeler, and C.W. Hamm et al. Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis J Am Coll Cardiol 45 2005 229 237
31. E.M. Antman, M.J. Tanasijevic, and B. Thompson et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes N Engl J Med 335 1996 1342 1349
32. S. James, P. Armstrong, and R. Califf et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial Am J Med 115 2003 178 184
33. M.A. Hlatky, P. Greenland, and D.K. Arnett et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 2009 2408 2416